AIM: To investigate the role of 3D ultrasound (3D-US) in target volume delineation in prostate cancer radiotherapy.
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
METHODS: Four patients with intermediate risk prostate cancer and metal artifacts on planning computed tomography (CT) due to previous bilateral hip replacement underwent 3D-US with the Clarity platform (Clarity System, Elekta, Stockholm, Sweden) to allow for image-guided procedures. Ultrasound and CT images were coregistered to allow for better delineation of the prostate gland and organs at risk (OAR). Electron density override (EDO) and standard electron density (EDS) methods were compared for appropriate dose calculation.
RESULTS: 3D-US and planning CT minimized image artifacts, providing better evidence of patient anatomy, particularly regarding soft tissue visualization. Prostate gland and seminal vesicles were better delineated, particularly in the posterior aspect. Anterior rectal wall and bladder neck were more visible. No difference was found in terms of average planning target volume dose, D15%, or D25% for rectum or D15%, D25%, or D35% of bladder between EDO and EDS.
CONCLUSIONS: 3D-US proved to be a viable tool for target volume and OAR visualization in patients with prostate cancer with hip prostheses.
Arcadipane F, Fiandra C, Franco P, Munoz F, Irgolini P, Trino E, Levis M, Guarneri A, Ricardi U. Are you the author?
Department of Oncology, Radiation Oncology, University of Turin, Turin - Italy.
Reference: Tumori. 2015 May 13;0(0):0.